Mga Batayang Estadistika
| LEI | 549300IDN7TWMQI0JP93 |
| CIK | 911216 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Palatin Technologies, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commiss |
|
| August 18, 2025 |
EXHIBIT 99.1 Date August 18, 2025 Page 01 | 02 Press release Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases · Collaboration strengthens Boehringer’s pipeline in Eye Health. · Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of inco |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2025 |
CERTIFICATE OF AMENDMENT THIRD RESTATED CERTIFICATE OF INCORPORATION PALATIN TECHNOLOGIES, INC. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF THIRD RESTATED CERTIFICATE OF INCORPORATION OF PALATIN TECHNOLOGIES, INC. Palatin Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the corporation (hereinafter called the “Corporation”) is Palatin Technologies, Inc. SECOND: The date of filing of the Ce |
|
| August 8, 2025 |
Palatin Announces 1-for-50 Reverse Stock Split EXHIBIT 99.1 Palatin Announces 1-for-50 Reverse Stock Split PRINCETON, NJ – August 8, 2025 /PRNewswire/ – Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-50. The Reverse Stock Split will become effective on August 8, 2025, at 5:00 p.m., Eastern Daylight Time (the “Effective Time”) and the Common Stock is expe |
|
| July 29, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commissio |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commission |
|
| July 1, 2025 | ||
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| June 13, 2025 |
EXHIBIT 3.1 CERTIFICATE OF DESIGNATION OF THE RIGHTS, POWERS, PREFERENCES, PRIVILEGES, AND RESTRICTIONS, OF THE SERIES D CONVERTIBLE PREFERRED STOCK OF PALATIN TECHNOLOGIES, INC. Palatin Technologies, Inc., a Delaware corporation (the “Corporation”), hereby certifies that, pursuant to the provisions of Sections 103, 141 and 151 of the General Corporation Law of the State of Delaware, on June 10, 2 |
|
| June 13, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| June 13, 2025 |
SERIES I COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES |
|
| May 8, 2025 |
Form of Series F Common Warrant EXHIBIT 4.1 FORM OF SERIES F COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| May 8, 2025 |
Palatin Technologies Announces Pricing of up to $23 Million Public Offering EXHIBIT 99.2 Palatin Technologies Announces Pricing of up to $23 Million Public Offering $11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J., May 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on |
|
| May 8, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 7, 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 8, 2025 |
Form of Series H Common Warrant EXHIBIT 4.3 FORM OF SERIES H COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [•] Initial Exercise Date: [•] THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t |
|
| May 8, 2025 |
EXHIBIT 99.1 Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice The Company Intends to Request a Review of the Delisting Determination CRANBURY, NJ – May 7, 2025 – Palatin Technologies, Inc. (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 7, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of i |
|
| May 8, 2025 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) File No. 333-286280 7,324,119 Shares of Common Stock 7,324,119 Series F Common Warrants to Purchase Up to 7,324,119 Shares of Common Stock 7,324,119 Series G Common Warrants to purchase Up to 7,324,119 Shares of Common Stock 7,324,119 Series H Common Warrants to purchase Up to 7,324,119 Shares of Common Stock 7,324,119 Shares of Common Stock Underlying t |
|
| May 8, 2025 |
Form of Series G Common Warrant EXHIBIT 4.2 FORM OF SERIES G COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES G COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| May 8, 2025 |
EXHIBIT 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 and Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 May 7, 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Attention: Carl Spana, Ph.D., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Spana: Subject to the terms and conditions of t |
|
| May 5, 2025 |
Form of Series G Common Warrant EXHIBIT 4.4 FORM OF SERIES G COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES G COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| May 5, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table S-1 (Form Type) Palatin Technologies, Inc. |
|
| May 5, 2025 |
Form of Series F Common Warrant. EXHIBIT 4.2 FORM OF SERIES F COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ☑ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth |
|
| May 5, 2025 |
Form of Series H Common Warrant EXHIBIT 4.5 FORM OF SERIES H COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [•], 2025 Initial Exercise Date: [•], 2025 THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| May 5, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025. As filed with the Securities and Exchange Commission on May 2, 2025. Registration No. 333-286280 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No.1 To FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4078884 (State or other jurisdiction of incorpo |
|
| May 5, 2025 |
Form of Securities Purchase Agreement, by and between the Company and the Purchasers named therein. EXHIBIT 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| May 2, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 May 2, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-286280) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 461 |
|
| May 2, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 May 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amen |
|
| April 15, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 15, 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 15, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) Filed March 31, 2025 File No. 333-286280 Ladies a |
|
| April 15, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on A |
|
| April 10, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on A |
|
| April 10, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 10, 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 10, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) Filed March 31, 2025 File No. 333-286280 Ladies a |
|
| April 10, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 10, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-286280) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 4 |
|
| April 10, 2025 |
EXHIBIT 99.1 Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal CRANBURY, NJ – April 10, 2025/PRNewswire/ – Palatin Technologies, Inc. (the “Company”) (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that on Ap |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commissi |
|
| April 10, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as a |
|
| April 7, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 7, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as am |
|
| April 7, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 7, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on Ap |
|
| April 7, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 7, 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 7, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) Filed March 31, 2025 File No. 333-286280 Ladies an |
|
| April 7, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 7, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-286280) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 46 |
|
| April 2, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 2, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-286280) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 46 |
|
| April 2, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as am |
|
| April 2, 2025 |
April 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-286280 Ladies and Gentlemen: The undersigned respectfully requests that the U.S. Securities and Exchange Commission (the “Commission”) c |
|
| April 2, 2025 |
April 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on March 31, 2025, in which we, as Lead Placement Agent for the proposed offering by Pa |
|
| April 2, 2025 |
April 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on March 31, 2025, in which we, as Lead Placement Agent for the proposed offering by Pa |
|
| April 2, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 2, 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 April 2, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 (the “Registration Statement”) Filed March 31, 2025 File No. 333-286280 Ladies and Gentlemen: Ref |
|
| March 31, 2025 |
EXHIBIT 99.1 Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 · Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. · Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks |
|
| March 31, 2025 |
EXHIBIT 99.2 Palatin AnnouncesMC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study · Primary endpoint met in the 8-week treatment study (highly statistically significant). o Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). · Primary analysis for the co-administered group in the 8 |
|
| March 31, 2025 |
EXHIBIT 4.2 FORM OF SERIES F COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES F COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| March 31, 2025 |
Form of Securities Purchase Agreement, by and between the Company and the Purchasers named therein. EXHIBIT 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2025, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| March 31, 2025 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 March 31, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-286280) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 4 |
|
| March 31, 2025 |
EXHIBIT 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: March [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| March 31, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025. As filed with the Securities and Exchange Commission on March 31, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4078884 (State or other jurisdiction of incorporation or organization) |
|
| March 31, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table S-1 (Form Type) Palatin Technologies, Inc. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): March 28, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| March 31, 2025 |
A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 March 31, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. Registration Statement on Form S-1 File No. 333-286280 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as a |
|
| March 31, 2025 |
EXHIBIT 10.49 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 and Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 March [ ], 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Attention: Carl Spana, Ph.D., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Spana: Subject to the terms and condition |
|
| March 7, 2025 |
Confidentially Submitted to the U.S. Securities and Exchange Commission on March 6, 2025. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECUR |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOG |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 11, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| February 12, 2025 |
EXHIBIT 1.1 PALATIN TECHNOLOGIES, INC. COMMON STOCK SALES AGREEMENT February 11, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Palatin Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Compan |
|
| February 12, 2025 |
Up to $6,000,000 of Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262555 Prospectus Supplement (to Prospectus dated September 26, 2022) Up to $6,000,000 of Shares of Common Stock On February 11, 2025, we entered into a certain Sales Agreement (the “sales agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”) relating to shares of our common stock offered by this prospectus supplement and the accompanying |
|
| February 10, 2025 |
Form of Series E Common Stock Purchase Warrant, issued on or about February 10, 2025 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 10, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262555 Prospectus Supplement (to Prospectus dated September 26, 2022) 2,550,000 Shares of Common Stock 2,138,000 Pre-Funded Warrants to Purchase up to 2,138,000 Shares of Common Stock 2,138,000 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering to a certain institutional investor (the “Investor”) 2,550,000 shares of our c |
|
| February 10, 2025 |
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement EXHIBIT 99.1 Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement CRANBURY, N.J., February 7, 2025 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it |
|
| February 10, 2025 |
EXHIBIT 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 and Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 February 6, 2025 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Attention: Carl Spana, Ph.D., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Spana: Subject to the terms and conditions |
|
| February 10, 2025 |
Form of Pre-Funded Common Stock Purchase Warrant, issued on or about February 10, 2025 EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, Inc. Warrant Shares: Issue Date: [•] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 6, 2025 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| February 10, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 6, 2025 between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| December 16, 2024 |
Form of Series C Common Stock Purchase Warrant, dated December 17, 2024. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 16, 2024 |
Form of Series D Common Stock Purchase Warrant, dated December 17, 2024. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 16, 2024 |
Inducement Letter, dated December 13, 2024. EXHIBIT 10.1 PALATIN TECHNOLOGIES, INC. 4B Cedar Brook Drive Cranbury, New Jersey 08512 December 13, 2024 To the Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: PALATIN TECHNOLOGIES, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder,” “you,” or similar terminology) the opportunity to rec |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| December 16, 2024 |
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds EXHIBIT 99.1 Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds CRANBURY, N.J., December 16, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLO |
|
| November 14, 2024 |
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results · Obesity programs: o Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates o Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ■ Patient enrollment completed October 2024 ■ Topline results expect |
|
| October 30, 2024 |
Up to 4,849,915 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-281007 PROSPECTUS Up to 4,849,915 Shares of Common Stock This prospectus relates to the offer and sale by the selling stockholders identified herein, or their permitted transferees (the “Selling Stockholders”), of up to an aggregate of 4,849,915 shares of common stock, par value $0.01 per share, of Palatin Technologies, Inc., consisting of (i) |
|
| October 25, 2024 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 October 25, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-281007) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule |
|
| October 22, 2024 |
As filed with the Securities and Exchange Commission on October 22, 2024 As filed with the Securities and Exchange Commission on October 22, 2024 Registration No. |
|
| October 7, 2024 |
Palatin Receives Notice of Non-Compliance from NYSE American EXHIBIT 99.1 Palatin Receives Notice of Non-Compliance from NYSE American CRANBURY, NJ – October 7, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the “Excha |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 4, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commiss |
|
| October 1, 2024 |
EXHIBIT 99.1 Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones · Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) o Patient Dosing Commenced 3Q Calendar Year 2024 o Patient Enrollment Expected to be Completed Early 4Q Cale |
|
| September 30, 2024 |
Palatin Technologies, Inc. Compensation Recovery Policy (Clawback Policy). EXHIBIT 97 ADOPTED RESOLUTIONS: CLAWBACK POLICY NOW, THEREFORE, BE IT RESOLVED, that the Corporation hereby adopts a clawback policy on the following terms and conditions, effective with respect to annual incentives, time-based restricted share units, performance-based restricted share units, stock options or other performance-based compensation granted on or after April 1, 2019: Each executive of |
|
| September 30, 2024 |
Subsidiaries of the registrant. EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT Name Under Which Name of Subsidiary State of Incorporation Name Under Which Subsidiary Does Business RhoMed Incorporated New Mexico RhoMed Incorporated |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (E |
|
| September 30, 2024 |
Palatin Technologies, Inc. Insider Trading and Securities Law Compliance Policy. EXHIBIT 19 INSIDER TRADING AND SECURITIES LAW COMPLIANCE POLICY OF PALATIN TECHNOLOGIES, INC. |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| August 20, 2024 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 August 20, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-281007) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule |
|
| August 20, 2024 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 August 20, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-281007) (the “Registration Statement”) Ladies and Gentlemen: The Company hereb |
|
| July 25, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Palatin Technologies, Inc. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| June 28, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| June 21, 2024 |
Form of Series A Common Stock Purchase Warrant, dated June 24, 2024. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 (June 20, 2024) Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission |
|
| June 21, 2024 |
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds EXHIBIT 99.1 Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds CRANBURY, N.J., June 21, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has ente |
|
| June 21, 2024 |
Inducement Letter, dated June 20, 2024. EXHIBIT 10.1 PALATIN TECHNOLOGIES, INC. 4B Cedar Brook Drive Cranbury, New Jersey 08512 June 20, 2024 To the Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: PALATIN TECHNOLOGIES, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the opportunity to receive |
|
| June 21, 2024 |
Form of Series B Common Stock Purchase Warrant, dated June 24, 2024. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| May 28, 2024 | ||
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES |
|
| May 15, 2024 |
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update · Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results o Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment Period o Rapid Onset of Efficacy and Multiple Symptom E |
|
| March 28, 2024 |
Up to 1,923,078 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-277934 Up to 1,923,078 Shares of Common Stock This prospectus relates to the offer and sale by the selling stockholders identified herein, or their permitted transferees (the “Selling Stockholders”), of up to an aggregate of 1,923,078 shares of common stock, par value $0.01 per share, of Palatin Technologies, Inc., consisting of (i) |
|
| March 27, 2024 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 March 27, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-277934) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 4 |
|
| March 14, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Palatin Technologies, Inc. |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 15, 2024 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commi |
|
| February 15, 2024 |
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update · Palatin’s Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline o PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February o Oral PL8177 Phase 2 Clinical Study in Patients with Ulcerative Colitis – Interim Analysis |
|
| February 14, 2024 |
PTN / Palatin Technologies, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-ptn123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PALATIN TECHNOLOGIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 696077502 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOG |
|
| February 14, 2024 |
EXHIBIT 10.2 SPECIFIC TERMS IN THIS EXHIBIT HAVEBEEN REDACTED BECAUSE (1) SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATEOR CONFIDENTIAL; OR (2) DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTEA CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH TWO ASTERISKS [**]. ASSET PURCHASE AGREEMENT between COSE |
|
| February 14, 2024 |
EXHIBIT 4.3 AMENDMENT TO THE PALATIN TECHNOLOGIES, INC. COMMON STOCK PURCHASE WARRANTS This Amendment (this “Amendment”), dated as of January 24, 2024 (the “Effective Date”), is made and entered into by and between the Palatin Technologies, Inc., a Delaware corporation (the “Company”), and (the “Designee”) and relates to (i) the common stock purchase warrant to purchase up to shares of the Company |
|
| February 14, 2024 |
EXHIBIT 4.4 AMENDMENT TO THE PALATIN TECHNOLOGIES, INC. COMMON STOCK PURCHASE WARRANTS This Amendment (this “Amendment”), dated as of January 24, 2024 (the “Effective Date”), is made and entered into by and between the Palatin Technologies, Inc., a Delaware corporation (the “Company”), and (the “Investor”) and relates to (i) the common stock purchase warrant to purchase up to shares of the Company |
|
| February 1, 2024 |
Palatin Announces Closing of $10 Million Registered Direct Offering EXHIBIT 99.2 Palatin Announces Closing of $10 Million Registered Direct Offering CRANBURY, NJ – February 1, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously a |
|
| February 1, 2024 |
Form of Common Stock Purchase Warrant, dated February 1, 2024. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 1, 2024 |
Palatin Announces $10 Million Registered Direct Offering EXHIBIT 99.1 Palatin Announces $10 Million Registered Direct Offering CRANBURY, NJ – January 30, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agre |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): January 29, 2024 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| February 1, 2024 |
Form of Placement Agent Common Stock Purchase Warrant, dated February 1, 2024. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 1, 2024 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 29, 2024, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| February 1, 2024 |
1,831,503 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262555 Prospectus Supplement (to Prospectus dated September 26, 2022) 1,831,503 Shares of Common Stock We are offering 1,831,503 shares of our common stock, par value $0.01 per share pursuant to this prospectus supplement and the base prospectus in a registered direct offering. The offering price for each share of common stock and accompanying |
|
| December 20, 2023 |
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million EXHIBIT 99.1 Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million · Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million · Palatin’s focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, NJ – December 20, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 19, 2023 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| December 18, 2023 |
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American EXHIBIT 99.1 Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American CRANBURY, NJ – December 18, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): December 13, 2023 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| December 15, 2023 |
Up to 2,476,416 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275883 Prospectus Up to 2,476,416 Shares of Common Stock This prospectus relates to the offer and sale by the selling stockholders identified herein, or their permitted transferees (the “Selling Stockholders”), of up to an aggregate of 2,476,416 shares of common stock, par value $0.01 per share, of Palatin Technologies, Inc., consisting of (i) |
|
| December 14, 2023 |
Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 December 14, 2023 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Palatin Technologies, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-275883) (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rul |
|
| December 4, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Palatin Technologies, Inc. |
|
| December 4, 2023 |
As filed with the Securities and Exchange Commission on December 4, 2023 As filed with the Securities and Exchange Commission on December 4, 2023 Registration No. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLO |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| November 14, 2023 |
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update · · Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) o 570 Patients Enrolled o Topline Data Currently Expected Late 4Q Calendar Year 2023 · Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis o Interim Analysis Targeted for 1Q Calendar Year |
|
| October 24, 2023 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 20, 2023, between Palatin Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| October 24, 2023 |
Form of Common Stock Purchase Warrant, dated October 24, 2023. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 24, 2023 |
PTN - Palatin Announces $5 Million Registered Direct Offering EXHIBIT 99.1 PTN - Palatin Announces $5 Million Registered Direct Offering CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive |
|
| October 24, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262555 Prospectus Supplement (to Prospectus dated September 26, 2022) 1,325,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,033,491 Shares of Common Stock Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 1,325,000 shares of our common stock, par value $0.01 per share pursuant to this prospectus supple |
|
| October 24, 2023 |
Form of Pre-Funded Common Stock Purchase Warrant. EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 20, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| October 24, 2023 |
Form of Placement Agent Common Stock Purchase Warrant, dated October 24, 2023. EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| October 19, 2023 |
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results EXHIBIT 99.1 Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results · 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed · $4.6 million in Gross Product Revenue o 11% growth over prior quarter; 100% growth over comparable quarter last year · $2.1 million in Net Product Revenue o 18% growth over prior quarter; 137% g |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| October 13, 2023 |
EXHIBIT 99.1 Palatin Receives Notice of Non-Compliance from NYSE American Palatin to Deliver Plan of Compliance to NYSE American CRANBURY, NJ – October 13, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (E |
|
| September 28, 2023 |
2011 Stock Incentive Plan, as amended, restated and adopted by the stockholders on June 20, 2023. EXHIBIT 10.11 PALATIN TECHNOLOGIES, INC. 2011 STOCK INCENTIVE PLAN, AS AMENDED AND RESTATED 1. Establishment, Purpose, Duration. a. Establishment. Palatin Technologies, Inc. (the “Company”) established an equity compensation plan known as the Palatin Technologies, Inc. 2011 Stock Incentive Plan (the “Plan”) effective as of March 11, 2011 (the “Effective Date”). The Company’s stockholders originall |
|
| September 28, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 28, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employ |
|
| September 28, 2023 |
EXHIBIT 99.1 Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update · Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled o Topline Data Expected Late 4Q Calendar Year 2023 o Interim Analysis of Initial 120 Patients Showed – Statistical Separation for Clinical Efficacy Across Multiple Signs a |
|
| September 28, 2023 |
Subsidiaries of the registrant. EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation Name Under Which Subsidiary Does Business RhoMed Incorporated New Mexico RhoMed Incorporated |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 7, 2023 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| September 8, 2023 |
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference EXHIBIT 99.1 Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference Cranbury, NJ, September 7, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwrig |
|
| September 7, 2023 |
EXHIBIT 99.1 Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease · Topline data currently expected late 4Q calendar 2023 · Interim analysis of first 120 patients demonstrated: o Excellent safety and tolerability product profile o Potential for PL9643 to address multiple signs and symptoms of dry eye disease CRANBURY, NJ – September 7, |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 7, 2023 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commi |
|
| August 10, 2023 |
EXHIBIT 99.1 Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment · ~30-40% of ED patients do not respond to PDE5i treatment · Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i · Successfully co-formulated bremelanotide with a PDE5i · P |
|
| August 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| August 8, 2023 |
Palatin Provides Update on VYLEESI® Collaborations EXHIBIT 99.1 Palatin Provides Update on VYLEESI® Collaborations · Licensee Fosun Pharma Reports First Commercial Sale in China o First prescription dispensed in Chinese Hainan Province · South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study o 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorde |
|
| August 7, 2023 |
EXHIBIT 99.1 Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi® Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth’s Women’s Health Platform CRANBURY, NJ – August 7, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in- |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| August 4, 2023 |
Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference EXHIBIT 99.1 Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference Cranbury, NJ, August 4, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will participate at the Canaccord Genui |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 4, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| July 11, 2023 |
Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi®Product Revenue Results EXHIBIT 99.1 Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi®Product Revenue Results · $4.1 million in Gross Product Revenue o 20% growth over 3Q23; 78% growth over 4Q22 · $1.7 million in Net Product Revenue o 42% growth over 3Q23; 122% growth over 4Q22 · 14% growth in prescriptions dispensed over 3Q23; 89% growth over 4Q22 o 6 consecutive quarters of double-digit growth · 20% gro |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 11, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| May 30, 2023 |
EXHIBIT 99.1 Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference – Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy – Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a b |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 30, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e) |
|
| May 16, 2023 |
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update · Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event o Analysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability o Fina |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| May 12, 2023 |
EXHIBIT 99.1 Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 CRANBURY, N.J., May 11, 2023 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call |
|
| May 9, 2023 |
EXHIBIT 99.1 Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar CRANBURY, N.J., May 8, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader (KOL) webin |
|
| May 9, 2023 |
EXHIBIT 99.2 Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference – Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease – Clinical data confirms PL8177 oral formulation is delivered and contained in the colon – Phase 2 clinical study data readout in 2H2023 CRANBURY, N.J., May 9, 2023 /PRNewswire/ |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of i |
|
| May 1, 2023 |
EXHIBIT 99.1 Palatin Technologies to Host Key Opinion Leader Webinar – Review of Phase 3 PL9643 Data for Dry Eye Disease – Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease – Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET CRANBURY, N.J., May 1, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing f |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of i |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| April 27, 2023 |
EXHIBIT 99.1 Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference - Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating prod |
|
| April 25, 2023 |
EXHIBIT 99.1 Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma - Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure - Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, NJ – April 25, 2023 /PRNewswire/ – Palatin Technolog |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| April 19, 2023 |
PALATIN ANNOUNCES PRELIMINARY THIRD QUARTER FISCAL 2023 VYLEESI® PRODUCT REVENUE RESULTS EXHIBIT 99.1 PALATIN ANNOUNCES PRELIMINARY THIRD QUARTER FISCAL 2023 VYLEESI® PRODUCT REVENUE RESULTS $3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth over 2Q23; 469% growth over 3Q22 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 5 consecutive quarters of double-digit growth CRANBURY, N.J., Apr |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer o |
|
| April 12, 2023 |
EXHIBIT 1.1 PALATIN TECHNOLOGIES, INC. $50,000,000 EQUITY DISTRIBUTION AGREEMENT April 12, 2023 Canaccord Genuity LLC 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: Palatin Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as of the date first written above, as follows: 1. Is |
|
| April 12, 2023 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262555 Prospectus Supplement (to Prospectus dated September 26, 2022) Up to $50,000,000 Common Stock We have entered into an equity distribution agreement with Canaccord Genuity LLC, or Canaccord, as sales agent, relating to shares of our common stock, $0.01 par value per share, offered by this prospectus supplement and the base prospectus. In |
|
| February 15, 2023 |
### (Financial Statement Data Follows) EXHIBIT 99.1 Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update · Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing o Patient Enrollment on Track o Topline Results Currently Expected Mid-Calendar Year 2023 · Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced o First Patient Dosed o Planned Interim |
|
| February 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 15, 2023 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| February 14, 2023 |
EXHIBIT 3.4 CERTIFICATE OF ELIMINATION OF PALATIN TECHNOLOGIES, INC. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, Palatin Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as f |
|
| February 14, 2023 |
US6960775020 / PALATIN TECHNOLOGIES INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOG |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLO |
|
| November 14, 2022 |
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update · Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing ☐ Positive Interim Analysis – DMC Recommended Study Size of 350 patients ☐ Topline Results Currently Expected Second Quarter Calendar 2023 · Vyleesi® - Net Product Revenue Increased 13% and Prescriptions Dispensed Inc |
|
| November 2, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| November 2, 2022 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 31, 2022, between Palatin Technologies, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and condi |
|
| November 2, 2022 |
Palatin Announces $10 Million Registered Direct Offering EXHIBIT 99.1 Palatin Announces $10 Million Registered Direct Offering CRANBURY, NJ ? October 31, 2022 /PRNewswire/ ? Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with a single healthcar |
|
| November 2, 2022 |
Form of Placement Agent Warrant EXHIBIT 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, Inc. Warrant Shares: Issue Date: November 2, 2022 Initial Exercise Date: May 2, 2023 THIS Placement Agent COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter |
|
| November 2, 2022 |
EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, Inc. Warrant Shares: Issue Date: November 2, 2022 Initial Exercise Date: May 2, 2023 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| November 2, 2022 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, Inc. Warrant Shares: Issue Date: November 2, 2022 Initial Exercise Date: November 2, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| November 2, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262555 Prospectus Supplement (to Prospectus dated September 26, 2022) 1,020,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 798,182 Shares of Common Stock Common Warrants to Purchase up to 1,818,182 Shares of Common Stock Placement Agent Warrants to Purchase up to 90,909 Shares of Common Stock Shares of Common Stock Underlying |
|
| September 26, 2022 |
2011 Stock Incentive Plan, as amended on June 24, 2022. EXHIBIT 4.4 PALATIN TECHNOLOGIES, INC. 2011 STOCK INCENTIVE PLAN, AS AMENDED AND RESTATED 1. Establishment, Purpose, Duration. a. Establishment. Palatin Technologies, Inc. (the ?Company?) established an equity compensation plan known as the Palatin Technologies, Inc. 2011 Stock Incentive Plan (the ?Plan?) effective as of March 11, 2011 (the ?Effective Date?). The Company?s stockholders originally |
|
| September 26, 2022 |
Common Stock Preferred Stock Debt Securities Purchase Contracts 424B3 1 ptn424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) File No. 333-262555 PROSPECTUS $100,000,000 Common Stock Preferred Stock Debt Securities Warrants Purchase Contracts Units From time to time, we may sell up to an aggregate of $100,000,000 of our common stock, preferred stock, debt securities, warrants, purchase contracts or units in any combination of the foregoing, in amounts, at prices |
|
| September 26, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Palatin Technologies Inc. |
|
| September 26, 2022 |
As filed with the Securities and Exchange Commission on September 26, 2022 S-8 1 ptns8.htm FORM S-8 As filed with the Securities and Exchange Commission on September 26, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (State or other jurisdiction of incorpo |
|
| September 23, 2022 |
As filed with the United States Securities and Exchange Commission on September 23, 2022 As filed with the United States Securities and Exchange Commission on September 23, 2022 Registration No. |
|
| September 23, 2022 |
[Letterhead of Palatin Technologies, Inc.] [Letterhead of Palatin Technologies, Inc.] September 23, 2022 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Palatin Technologies, Inc. Registration Statement on Form S-3 (File No. 333-262555) Acceleration Request Ladies and Gentleman: Pursuant to Rule 461 of Regulation C promulgated under the Securities Act |
|
| September 23, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Palatin Technologies Inc. |
|
| September 22, 2022 |
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update ? Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis ? DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter Calendar 2023 ? Vyleesi? - Gross product sales increased 79%, net product revenue in |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (E |
|
| September 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employ |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 30, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer |
|
| August 31, 2022 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF PALATIN TECHNOLOGIES, INC. Palatin Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the corporation (hereinafter called the ?Corporation?) is Palatin Technologies, Inc. SECOND: The date of filing of the Certific |
|
| August 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commiss |
|
| August 19, 2022 |
Press Release dated August 19, 2022 EXHIBIT 99.1 |
|
| June 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| June 24, 2022 |
EXHIBIT 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), effective as of this 1st day of July, 2022, is entered into by Palatin Technologies, Inc., a Delaware corporation with its principal place of business at 4B Cedar Brook Drive, Cranbury, NJ, 08512 (the ?Company?), and Stephen T. Wills (?Employee?). The Company desires to continue employing the Employee, and the Employee |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employer of |
|
| June 24, 2022 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), effective as of this 1st day of July, 2022, is entered into by Palatin Technologies, Inc., a Delaware corporation with its principal place of business at 4B Cedar Brook Drive, Cranbury, NJ, 08512 (the ?Company?), and Carl Spana (?Employee?). The Company desires to continue employing the Employee, and the Employee desire |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e) |
|
| May 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction of incorporation) (Commission |
|
| May 17, 2022 |
Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update ? Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 ? Vyleesi? - Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, ov |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOGIES |
|
| May 16, 2022 |
Form of Common Stock Purchase Warrant. EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 16, 2022 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 11, 2022, between Palatin Technologies, Inc., a Delaware corporation (the ?Company?), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and |
|
| May 16, 2022 |
Certificate of Decrease of Series A Convertible Preferred Stock. EXHIBIT 3.4 PALATIN TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATION OF SERIES C CONVERTIBLE REDEEMABLE PREFERRED STOCK (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) PALATIN TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that, pursuant to the authority conferred on the Board |
|
| May 16, 2022 |
Certificate of Elimination with respect to Series A Preferred Stock and Series B Preferred Stock. EXHIBIT 3.5 CERTIFICATE OF ELIMINATION OF PALATIN TECHNOLOGIES, INC. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, Palatin Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as f |
|
| May 16, 2022 |
Form of Common Stock Purchase Warrant. EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 16, 2022 |
Certificate of Designation of Series B Convertible Redeemable Preferred Stock. EXHIBIT 3.3 PALATIN TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE REDEEMABLE PREFERRED STOCK (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) PALATIN TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that, pursuant to the authority conferred on the Board |
|
| May 16, 2022 |
Certificate of Decrease of Series A Convertible Preferred Stock EXHIBIT 3.6 CERTIFICATE OF DECREASE OF PALATIN TECHNOLOGIES, INC. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, Palatin Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies that, a |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e) |
|
| February 15, 2022 |
Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update ? Initiated Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Expected Second Half Calendar 2022 ? Approximately $47.3 Million in Cash and Cash Equivalents at December 31, 2021 ? Projected Cash Runway through March 31, 2023 ? Phase 2 Clinical Study of PL8 |
|
| February 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): February 15, 2022 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLOG |
|
| February 7, 2022 |
EXHIBIT 5.01 February 4, 2022 Palatin Technologies, Inc. 4B Cedar Brook Drive Cranbury, New Jersey 08512 Re: Registration Statement on Form S-3 Ladies and Gentlemen: We have acted as counsel to Palatin Technologies, Inc., a Delaware corporation (the ?Company?), in connection with the preparation and filing by the Company of its registration statement on Form S-3 (the ?Registration Statement?) with |
|
| February 7, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Palatin Technologies Inc. |
|
| February 7, 2022 |
As filed with the United States Securities and Exchange Commission on February 4, 2022 As filed with the United States Securities and Exchange Commission on February 4, 2022 Registration No. |
|
| February 7, 2022 |
Exhibit 4.06 Form of Indenture PALATIN TECHNOLOGIES, INC. ISSUER and INDENTURE TRUSTEE INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 3 Section 1.01 Definitions. 3 Section 1.02 Other Definitions. 6 Section 1.03 Incorporation by Reference of Trust Indenture Act. 7 Section 1.04 Rules of Construction. 7 ARTICLE II TILE SECURITIES 8 Section 2.01 Issuable |
|
| November 15, 2021 |
Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update ? Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calendar 2022 ? Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start First Half Calendar 2022 with Top-Line R |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employe |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15543 PALATIN TECHNOLO |
|
| September 29, 2021 |
Exhibit 99.1 Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update ? Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 ? Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Q |
|
| September 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): September 29, 2021 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15543 95-4078884 (State or other jurisdiction (Commission (IRS employ |
|
| September 28, 2021 |
SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation Name Under Which Subsidiary Does Business RhoMed Incorporated New Mexico RhoMed Incorporated |
